,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'destiny04', 'bcsm', 'breast']
destiny04: in patients with her2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer pfs(10 vs 5 mo) and os (23 vs 17mo) than chemotherapy. grade 3/4 ae: 53%
ild: 12%
#asco22 #bcsm 
Breast Oncologist at @MontefioreNYC @EinsteinMed. Interested in Translational Research & Clinical Trials. Diversity & Inclusion. On weekends ???????
???? ????